Metabolic changes in the rodent brain after acute administration of salvinorin A

Molecular Imaging and Biology

Volumn 11, Issue 3, 2009, Pages 137-143

  Hooker, Jacob M ^a   Patel, Vinal ^a   Kothari, Shiva ^a   Schiffer, Wynne K ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Hallucinogen; Kappa opioid; Positron emission tomography; Salvia; SalvinorinA

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KAPPA OPIATE RECEPTOR AGONIST; SALVINORIN A; TRACER;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AUDITORY CORTEX; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM VERMIS; COGNITION; CONTROLLED STUDY; DRUG EFFECT; FEAR; FRONTAL CORTEX; HYPOTHALAMUS; LOCOMOTION; MALE; MOOD; MOTOR PERFORMANCE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RODENT; SENSORY CORTEX; STRIA TERMINALIS;

AFFECT; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN MAPPING; COGNITION; DITERPENES, CLERODANE; FLUORODEOXYGLUCOSE F18; LOCOMOTION; MALE; METABOLISM; MOTOR ACTIVITY; POSITRON-EMISSION TOMOGRAPHY; RATS; RECEPTORS, OPIOID, KAPPA;

ANIMALIA; RATTUS; RODENTIA; SALVIA;

EID: 67349123137     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0192-x     Document Type: Article

References (39)

1. Ossipov MH, Lai J, King T, Vanderah TW, Malan TP Jr, Hruby VJ, Porreca F (2004) Antinociceptive and nociceptive actions of opioids. J Neurobiol 61:126-148
2. Snyder SH, Pasternak GW (2003) Historical review: Opioid receptors. Trends Pharmacol Sci 24:198-205
3. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330
4. Jutkiewicz EM (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6:162-169
5. Pan ZZ (1998) mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 19:94-98
6. Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC, Hughes J (1990) CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol 101:183-189
7. Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, Chi ZQ, Long YQ, Liu JG (2008) LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. Eur J Pharmacol 584:306-311
8. Millan MJ (1990) Kappa-opioid receptors and analgesia. Trends Pharmacol Sci 11:70-76
9. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934-11939
10. Vortherms TA, Roth BL (2006) Salvinorin A: From natural product to human therapeutics. Mol Interv 6:257-265
11. Babu KM, McCurdy CR, Boyer EW (2008) Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila) 46:146-152
12. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M (2008) Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 63:286-292
13. Braida D, Limonta V, Pegorini S, Zani A, Guerini-Rocco C, Gori E, Sala M (2007) Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology 190:441-448
14. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179:551-558
15. Gehrke BJ, Chefer VI, Shippenberg TS (2008) Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology 197:509-517
16. Carlezon WA (2006) Neurobiological effects of salvinorin A in rodents: implications for the study and treatment of depressive disorders. Neuropsychopharmacology 31:S40-S41
17. Carlezon WA Jr., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440-447
18. John TF, French LG, Erlichman JS (2006) The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 545:129-133
19. Ansonoff MA, Zhang JW, Czyzyk T, Rothman RB, Stewart J, Xu H, Zjwiony J, Siebert DJ, Yang F, Roth BL, Pintar JE (2006) Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318:641-648
20. Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH (2005) Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 16:627-633
21. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen LY (2005) Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220-230
22. Butelman ER, Harris TJ, Kreek MJ (2004) The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 172:220-224
23. Lee DY, Karnati VV, He M, Liu-Chen LY, Kondaveti L, Ma Z, Wang Y, Chen Y, Beguin C, Carlezon WA Jr., Cohen B (2005) Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett 15:3744-3747
24. Alexoff DL, Vaska P, Marsteller D, Gerasimov T, Li J, Logan J, Fowler JS, Taintor NB, Thanos PK, Volkow ND (2003) Reproducibility of 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. J Nucl Med 44:815-822
25. Frumberg DB, Fernando MS, Lee DE, Biegon A, Schiffer WK (2007) Metabolic and behavioral deficits following a routine surgical procedure in rats. Brain Res 1144:209-218
26. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, New York
27. Schiffer WK, Mirrione MM, Dewey SL (2007) Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents. J Nucl Med 48:277-287
28. Schweinhardt P, Fransson P, Olson L, Spenger C, Andersson JL (2003) A template for spatial normalisation of MR images of the rat brain. J Neurosci Methods 129:105-113
29. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS (2008) Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset, short duration of effects in humans. Neuroimage 41:1044-1050
30. Holschneider DP, Yang J, Sadler TR, Nguyen PT, Givrad TK, Maarek JM (2006) Mapping cerebral blood flow changes during auditory-cued conditioned fear in the nontethered, nonrestrained rat. Neuroimage 29:1344-1358
31. Nobre MJ, Ribeiro dos Santos N, Aguiar MS, Brandao ML (2000) Blockade of mu- and activation of kappa-opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze. Eur J Pharmacol 404:145-151
32. Yakusheva TA, Shaikh AG, Green AM, Blazquez PM, Dickman JD, Angelaki DE (2007) Purkinje cells in posterior cerebellar vermis encode motion in an inertial reference frame. Neuron 54:973-985
33. Buzsaki G, Kaila K, Raichle M (2007) Inhibition and brain work. Neuron 56:771-783
34. Beguin C, Richards MR, Li JG, Wang Y, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM (2006) Synthesis and in vitro evaluation of salvinorin A analogues: Effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett 16:4679-4685
35. Lee DYW, Ma ZZ, Liu-Chen LY, Wang YL, Chen Y, Carlezon WA, Cohen B (2005) New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Bioorg Med Chem 13:5635-5639
36. Holden KG, Tidgewell K, Marquam A, Rothman RB, Navarro H, Prisinzano TE (2007) Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Exploration of the 1-position. Bioorg Med Chem Lett 17:6111-6115
37. Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA Jr., Cohen BM, Beguin C (2008) Standard protecting groups create potent and selective kappa opioids: Salvinorin B alkoxymethyl ethers. Bioorg Med Chem 16:1279-1286
38. Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, Liu-Chen LY (2008) 2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther 324:1073-1083
39. Siebert DJ (1994) Salvia divinorum and salvinorin A: New pharmacologic findings. J Ethnopharmacol 43:53-56